Baxter reports financial results

07/22/2010 | Wall Street Journal, The

Baxter International reported a decrease in earnings for the second quarter, owing to economic and product issues. The company expects sales of its plasma protein and antibody therapy products to decline for the rest of the year because of continued market issues. It also said it has stepped up its strategies to strengthen sales of Gammagard, a plasma-based drug.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC